Description of the medicine: Kurosurf (Curosurf)
Surfactant containing a phospholipid fraction (practant alpha) and low molecular weight hydrophobic proteins (about 1%) isolated from pig lungs.
It is prescribed for respiratory distress syndrome associated with surfactant deficiency in newborns (premature) children (with a body weight of at least 700 g). The use of the drug is designed to restore adequate breathing (oxygenation).
Enter intratracheally in the form of instillation of 2.5 ml of suspension per 1 kg of body weight. Then, using a breathing bag, ventilation of the lungs is carried out manually for 1-2 minutes.
For selective distribution, the drug can be injected into each lung at 1.25 ml / kg of surfactant 2 times with an interval of 1 min, while turning the child in the appropriate direction and after each injection, conducting manual ventilation.
Repeated instillations (if required) are carried out with an interval of at least 12 hours (up to 4 instillations in total).
The use of the drug is allowed only in clinical conditions (given the need for mechanical ventilation and monitoring).
Release form: 8% suspension in bottles of 1.5 and 3 ml (in 1 ml of 0.08 g (80 mg) of phospholipids).
Storage: at temperatures from +2 to +8 ° С.